Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Avantis International Equity ETF (NY:AVDE)

91.38 -0.14 (-0.15%)
Official Closing Price Updated: 4:10 PM EDT, May 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Avantis International Equity ETF

< Previous 1 2 Next >
News headline image
Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock ↗
BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday. 
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy ↗
Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing. 
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
Mason Buys Over $3 Million of COWG ↗
This ETF targets U.S. large-cap companies with strong free cash flow, using a systematic approach to identify growth leaders. 
Via The Motley Fool
Topics ETFs
Novo Nordisk Reportedly Slashes Workforce At Its US Wegovy Manufacturing Plant ↗
Via Stocktwits
Novo Nordisk To Reportedly Cut Yearly Bonus For Denmark Employees: Retail Expects Stock To Hit $80 By Year-End ↗
Via Stocktwits
News headline image
Novo Nordisk To Cut Ozempic, Wegovy Prices By Up To 50%: Report ↗
According to a report by The Wall Street Journal, Ozempic and Wegovy prices will start at a list price of $675 a month, effective Jan. 1, 2027. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
NVO Stock Continues To Decline Pre-Market After Monday’s Crash Amid CagriSema Setback – But Tuesday Brings Some Hope From China ↗
Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China. 
Via Stocktwits
News headline image
Why Is NVO Stock Falling Pre-Market Today? ↗
The company stated that CagriSema demonstrated 23% weight loss in people with obesity, failing to meet its primary endpoint. 
Via Stocktwits
Topics Government
News headline image
Novo Nordisk Reportedly Eyes Launching Wegovy In Vials To Compete With Rival Eli Lilly ↗
Bloomberg reported on Wednesday, citing Novo CEO Mike Doustdar, that the vials are slated to be introduced in the U.S. this year. 
Via Stocktwits
Topics Intellectual Property
News headline image
FDA Says Novo's Wegovy Pill TV Advertisement Is Misleading: NVO Stock Pares Gains ↗
According to an FDA letter dated February 5, the agency stated that the advertisement “misbrands” Wegovy. 
Via Stocktwits
Topics Lawsuit
News headline image
Novo Nordisk Sues Hims & Hers Over Compounded Wegovy, Calls For Permanent Sales Ban: HIMS Stock Tanks ↗
Novo stated that it has filed the lawsuit to protect its intellectual property and the American public. 
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
Budweiser Maker’s Stock Gets Crushed After Q2 Gloom — Retail Traders Feel 'Drop Is A Bit Unjustified' ↗
U.S.-listed shares of the world's largest brewer marked their worst day in over five years after the company missed revenue and volume estimates. 
Via Stocktwits
Topics Government
News headline image
US Judge Upholds FDA Decision To Remove Wegovy, Ozempic From Shortage List In Move Against Compounding Pharmacies ↗
The judge said that the FDA had appropriately weighed supply and demand data for the drugs and properly removed them from the shortage list, Reuters reported. 
Via Stocktwits
Topics Lawsuit
News headline image
Novo Nordisk’s Plan To Start Late-Stage Trial Of Investigational Obesity Drug Amycretin In 2026 Gets Retail Talking ↗
The decision to advance the study of subcutaneous and oral Amycretin into the late stage is based on feedback received from regulators following mid-stage studies. 
Via Stocktwits
News headline image
Novo Nordisk’s $812M Deal With Deep Apple Lifts Retail Mood, Chatter Spikes To High Levels ↗
Separately, chip-maker Nvidia also announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases. 
Via Stocktwits
Topics Artificial Intelligence Economy
News headline image
Toyota Industries Likely To Accept $42B Takeover Bid From Toyota Motor And Group Companies, Says Report: Retail’s Undecided ↗
The consortium is expected to take Toyota Industries private after it accepts the tender offer, with the takeover bid estimated at 6 trillion yen, or approximately $42 billion. 
Via Stocktwits
Topics Supply Chain
News headline image
Toyota Records Fourth Straight Month Of Sales Jump In April: But Retail’s Not Yet Convinced ↗
The company reported a 25% jump in sales of electrified vehicles last month, owing to a 24% increase in sales of hybrid electric vehicles in particular, which touched 378,976 units. 
Via Stocktwits
Topics Government World Trade
News headline image
Novo Nordisk To Sell Wegovy For $199 A Month As Compounding Ban Nears: Retail’s Bullish ↗
The offer will be valid through June 30 and aims to encourage patients who previously used compounded versions of the drug to move to Wegovy. 
Via Stocktwits
News headline image
Novo Nordisk CEO Lars Jørgensen Steps Down Amid Challenges, Retail Chatter Spikes ↗
The company said it would announce the next CEO in “due course,” but did not provide a more definite timeline. 
Via Stocktwits
News headline image
Budweiser Maker AB InBev Plans $300M Investment To Expand US Production: Retail Turns Bullish ↗
As part of the plan, the company will also open a new plant in Ohio. 
Via Stocktwits
Topics Government
News headline image
Toyota Expects 21% Profit Decline In FY26: Retail’s In Wait-And-Watch Mode ↗
The company said that the new forecast includes a negative impact of 180 billion yen from U.S. tariffs for April and May, and an estimated 745 billion yen impact from the effects of the foreign... 
Via Stocktwits
Topics World Trade
News headline image
Novo Nordisk Stock Rises Pre-Market On Q1 Beat Despite Lowering Outlook – Retail’s Elated ↗
Sales of Novo Nordisk’s flagship weight loss drug Wegovy surged 85% in the first quarter of the fiscal year 2025, while its diabetes treatment Ozempic posted an 18% increase. 
Via Stocktwits
Topics Earnings Law Enforcement
News headline image
Why Is UBS Stock Trading Lower On Wednesday? ↗
UBS Group AG shares are down 1% Y/Y, with revenues of $12.56 billion missing consensus. CEO remains focused on clients and financial targets. 
Via Benzinga
News headline image
Novo Nordisk’s Weight-Loss Drug Wegovy Launched In Thailand, Marks Entry Into Southeast Asia ↗
Enrico Canal Bruland, vice president and general manager of Novo's Thai subsidiary, told Reuters that the firm received approval from the Thai FDA in 2023. 
Via Stocktwits
News headline image
Novo Nordisk Wins Another Legal Battle Against Compounding Of Wegovy, Ozempic: Retail’s Bullish ↗
Steve Benz, legal and US general counsel of Novo Nordisk, said the company is “pleased” that the court rejected the compounders' attempts to “undermine” the FDA's decision that the shortages of Wegovy... 
Via Stocktwits
Topics Lawsuit
News headline image
Genmab Stock Rises On Strong Darzalex Sales In Q1: Retail Remains Extremely Bullish ↗
Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and subcutaneous products, under J&J's exclusive worldwide license to develop, manufacture, and commercialize... 
Via Stocktwits
Topics Stocks
News headline image
Novo Nordisk Warns Against Counterfeit Ozempic In US: Retail’s Unmoved ↗
The company said the seized counterfeit products feature lot number PAR0362 and illegitimate serial numbers beginning with the first eight digits, 51746517. 
Via Stocktwits
Topics Economy
News headline image
Novo Nordisk’s Controlling Shareholder Novo Holdings Reports Record Total Income, Investment Returns In 2024: Retail Stays Bullish ↗
The company said that its earnings consist of income from dividends and the share repurchase programmes of Novo Group companies Novo Nordisk A/S and Novonesis A/S, as well as returns from its... 
Via Stocktwits
News headline image
Novo Nordisk Stock Slips After BofA, Morgan Stanley Slash Price Targets – But Retail Goes Contrarian ↗
Bank of America analysts said Novo Nordisk might miss first-quarter estimates. According to TheFly, they expect the company to lower its full-year sales guidance from 16%-24% at constant exchange rates... 
Via Stocktwits
News headline image
Novo Nordisk Signs $2B Deal For Obesity Drug With Chinese Biotech: Retail Sentiment Improves ↗
Novo Nordisk will obtain exclusive worldwide rights to develop, manufacture, and commercialize the drug UBT251, while United Biotechnology will, however, retain the rights to the drug in mainland... 
Via Stocktwits
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.